SIREN : 808264550
DR GRIJALVO is a French company founded 11 years ago, specialized in the sector Évaluation des risques et dommages. Based in CASTILLON (06500), this company of category PME shows in 2021 a revenue of 149 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Kennzahl | 2021 |
|---|---|
| Umsatz | 148 690 € |
| Nettoergebnis | 90 354 € |
| EBITDA | 126 421 € |
| Nettomarge | 60.8% |
In 2021, DR GRIJALVO achieves revenue of 149 k€. After deducting consumption (0 €), gross margin stands at 149 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 126 k€, representing 85.0% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 90 k€, i.e. 60.8% of revenue. This profit can be retained or distributed to shareholders.
148 690 €
148 690 €
126 421 €
118 589 €
90 354 €
85.0%
The debt ratio (= Financial debt / Equity x 100) stands at 3%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 88%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 63.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
3.077%
88.008%
63.831%
0.062
77.8%
In 2021, the debt ratio of DR GRIJALVO (3.08) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2021, the financial autonomy of DR GRIJALVO (88.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2021, the repayment capacity of DR GRIJALVO (0.06) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 914.10. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
914.101
0.0
In 2021, the liquidity ratio of DR GRIJALVO (914.10) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2021, the interest coverage of DR GRIJALVO (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 22 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 3 days. The company must finance 19 days of gap between collections and payments. WCR is negative (-39 days): operations structurally generate cash.
-16 218 €
22 j
3 j
0 j
-39 j
Indicative estimate only : the number of comparable transactions in this sector is limited (45 transactions). This range of 40 771€ to 242 590€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 45 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DR GRIJALVO with other companies in the same sector:
Voir toutes les statistiques du secteur Évaluation des risques et dommages
The revenue of DR GRIJALVO in 2021 is 149 k€.
Yes, DR GRIJALVO generated a net profit of 90 k€ in 2021.
The headquarters of DR GRIJALVO is located in CASTILLON (06500), in the department Alpes-Maritimes.
The tax return of DR GRIJALVO is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DR GRIJALVO operates in the sector Évaluation des risques et dommages (NAF code 66.21Z). See the 'Sector positioning' section above to compare the company with its competitors.